Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company... 19 KB (1,171 words) - 14:44, 10 April 2024 |
Smallpox vaccine (redirect from Modified vaccinia Ankara - Bavarian Nordic) Into the Strategic" (Press release). Retrieved 4 July 2022. Bavarian Nordic. "Bavarian Nordic Announces U.S. FDA Approval of Jynneos (Smallpox and Monkeypox... 112 KB (12,132 words) - 09:38, 14 April 2024 |
1 July 2020. Retrieved 16 July 2020 – via Reuters. Bavarian Nordic (15 July 2015). "Bavarian Nordic announces that the Oxford Vaccines Group has initiated... 66 KB (6,054 words) - 23:56, 2 April 2024 |
developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic. On 9 August 2021, it was announced that the first round of trials... 3 KB (170 words) - 14:16, 24 August 2023 |
commercialise PROSTVAC, Bavarian Nordic's phase III prostate-specific antigen targeting cancer immunotherapy. Bavarian Nordic would receive an upfront... 91 KB (7,411 words) - 12:29, 22 March 2024 |
OMX Copenhagen 25 (category Nasdaq Nordic) top-tier stock market index for Nasdaq Copenhagen, which is part of the Nasdaq Nordic, prior being replaced (as of December 2017) was known as OMX Copenhagen... 9 KB (144 words) - 14:23, 9 February 2024 |
glafolivec) is a cancer immunotherapy candidate in clinical development by Bavarian Nordic for the treatment of all prostate cancer although clinical trials are... 6 KB (705 words) - 15:06, 27 November 2023 |